SCHEMBL22200816

SCHEMBL22200816

CC(C)n1c(=O)c(-c2cc(F)c(NSCc3ccc(C(F)F)cc3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.38
USP2 O75604 11/20 0.34
CASP1 P29466 9/20 0.34
CYP1A2 P05177 9/20 0.34
HIF1A Q16665 8/20 0.34
CASP7 P55210 8/20 0.34
TSHR P16473 4/20 0.34
MTOR P42345 4/20 0.33
CYP3A4 P08684 8/20 0.33
CYP2C9 P11712 5/20 0.33
ALDH1A1 P00352 9/20 0.32
HSD17B10 Q99714 7/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
CLK4 Q9HAZ1 2/20 0.32
GLA P06280 1/20 0.32
CYP2C19 P33261 3/20 0.32
MAPK1 P28482 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200788 0.93 USP2 (0.40) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200826 0.92 ERN1 (0.39) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200635 0.91 ERN1 (0.39) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200549 0.86 ERN1 (0.37) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL25034231 0.85 ERN1 (0.46) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200603 0.83 ERN1 (0.43) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200594 0.82 RORC (0.34) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200719 0.81 ERN1 (0.42) ERN1USP2CASP1CYP1A2HIF1A
SCHEMBL22200799 0.81 RORC (0.34) ERN1MTORRORC
SCHEMBL22200338 0.81 ERN1 (0.41) ERN1USP2CASP1CYP1A2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed